The DOI matches its Crossref record; 253 of the 258 references it cites were found in a registry or an index; 121 of the 229 sources its claims cite were checked for support.
The use of neuroimaging techniques in the early and differential diagnosis of dementia
Open accessAbstract
Abstract Dementia is a leading cause of disability and death worldwide. At present there is no disease modifying treatment for any of the most common types of dementia such as Alzheimer’s disease (AD), Vascular dementia, Lewy Body Dementia (LBD) and Frontotemporal dementia (FTD). Early and accurate diagnosis of dementia subtype is critical to improving clinical care and developing better treatments. Structural and molecular imaging has contributed to a better understanding of the pathophysiology of neurodegenerative dementias and is increasingly being adopted into clinical practice for early and accurate diagnosis. In this review we summarise the contribution imaging has made with particular focus on multimodal magnetic resonance imaging (MRI) and positron emission tomography imaging (PET). Structural MRI is widely used in clinical practice and can help exclude reversible causes of memory problems but has relatively low sensitivity for the early and differential diagnosis of dementia subtypes. 18 F-fluorodeoxyglucose PET has high sensitivity and specificity for AD and FTD, while PET with ligands for amyloid and tau can improve the differential diagnosis of AD and non-AD dementias, including recognition at prodromal stages. Dopaminergic imaging can assist with the diagnosis of LBD. The lack of a validated tracer for α-synuclein or TAR DNA-binding protein 43 (TDP-43) imaging remain notable gaps, though work is ongoing. Emerging PET tracers such as 11 C-UCB-J for synaptic imaging may be sensitive early markers but overall larger longitudinal multi-centre cross diagnostic imaging studies are needed.
Overview
CoChat Summary
## TL;DR
This review argues that neuroimaging is now central to the early and differential diagnosis of dementia, with MRI and PET providing complementary information about structure, metabolism, pathology, and prognosis. It concludes that structural MRI is widely used but relatively insensitive early on, while FDG-PET, amyloid/tau PET, and dopaminergic imaging offer stronger diagnostic value for specific dementia subtypes.
## Key findings
- Structural MRI can help exclude alternative causes and support subtype diagnosis, but the paper says its role is mainly to corroborate a clinical syndrome and that volumetric MRI has “relatively low sensitivity” for early and differential diagnosis.
- Reported diagnostic performances include:
- Atrophy maps: 90% sensitivity / 84% specificity for AD, 78.7% / 98.8% for LBD, and 84.4% / 93.8% for FTD.
- A study with 504 individuals reported MRI accuracy of 70.6% overall; VaD sensitivity 96%, controls 82%, AD 74%, and DLB only 24% sensitivity.
- FDG-PET meta-analytic performance for AD vs controls was 90% sensitivity / 89% specificity; for AD vs non-AD dementias, a systematic review found median sensitivity 0.89 and specificity 0.74.
- For dementia subtypes:
- FDG-PET in DLB showed 74% sensitivity / 70% specificity in larger studies, and the “cingulate island” sign was noted as a supportive feature.
- FP-CIT SPECT differentiated DLB from AD with 78% sensitivity / 91% specificity; in 144 MCI patients, it was 76% accurate for probable MCI-DLB.
- Amyloid PET was reported as more sensitive than FDG-PET for AD vs FTD (89% vs 73%) but less specific (83% vs 98%).
- Tau PET in a multicentre study of 719 participants had 89.9% sensitivity / 90.6% specificity for AD vs non-AD neurodegenerative disorders, with AUC 0.92–0.95.
- The review highlights emerging markers such as 11C-UCB-J synaptic PET and advanced MRI methods, but says these still need larger, longitudinal, multicentre validation.
## Methods
- Narrative review of diagnostic brain imaging in dementia, focusing on structural MRI, DTI/NODDI, perfusion MRI/ASL, fMRI, FDG-PET, amyloid PET, tau PET, dopaminergic imaging, and other PET ligands.
- Synthesizes evidence from studies spanning AD, DLB/LBD, FTD, VaD, MCI, and control groups; several cited studies include sample sizes such as 504, 571 + 551 + 212 + 125 + 271, 719, and 1431 participants.
- Main analysis is qualitative comparison of reported diagnostic accuracy, subtype patterns, and prognostic value across imaging modalities, with emphasis on sensitivity, specificity, and AUC where available.
## Limitations
- The paper states that many methods still need larger, longitudinal, multicentre cross-diagnostic studies before routine clinical translation.
- It notes that several approaches have modest or inconsistent performance in early disease: volumetric MRI has low sensitivity in prodromal stages, ASL and fMRI show overlap across groups, and FDG-PET is not recommended for clinical use at the MCI stage because of variable sensitivity/specificity.
- Evident from the text: much of the evidence comes from single-site, highly selected research cohorts, and the paper explicitly warns that reported sensitivities/specificities are likely overestimated relative to real-world practice.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
88 Valid · 4 Not valid · 46 Not checked · 12 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Larger studies however have shown that FDG-PET has sensitivity of 74% and specificity of 70% for DLB and therefore cannot be used as an indicative biomarker [21, 110].”
§ The use of neuroimaging techniques in the early and differential diagnosis of dementia > 18F-Fluorodeoxyglucose (FDG) PET
What the sources say
- Disputedcites [21] McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology. 2017;66:1455. sourceExperimental — accuracy not yet measured
The Biomarkers section reports the figures in the opposite order: sensitivity 70% and specificity 74% in larger studies earlier in disease. It also says these values are slightly lower than needed for an indicative biomarker. No page number is provided in our copy. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
- Not checked yetcites [110] O’Brien JT, Firbank MJ, Davison C, Barnett N, Bamford C, Donaldson C, et al. 18F-FDG PET and perfusion SPECT in the diagnosis of alzheimer and lewy body dementias. J Nucl Med. 2014;55:1959–65. source
Checked before — its earlier verdict is held back until a new check runs.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Koppel et al. compared 134 cases with AD, FTD, LBD and MCI and were able to separate healthy elderly from patients with dementia with an AUC of 0.97 [16].”
§ The use of neuroimaging techniques in the early and differential diagnosis of dementia > Structural MRI > Volumetric MRI
What the sources say
- Partly supportedcites [16] Klöppel S, Peter J, Ludl A, Pilatus A, Maier S, Mader I, et al. Applying automated MR-based diagnostic methods to the memory clinic: a prospective study. J Alzheimer’s Dis. 2015;47:939–54. sourceExperimental — accuracy not yet measured
The Results (Differential diagnostics of dementia; page unavailable) report an AUC of 0.97 for separating healthy controls from the other diagnostic groups. However, the Abstract distinguishes the 134 local-clinic cases used for differential diagnosis from the separate MCI progression analysis, so describing all 134 as cases with AD, FTD, LBD and MCI is not supported. (LLM, conf=0.88)
plainstates an associationn = 134- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In all the degenerative dementias the onset of symptoms is associated with already established brain pathology, which develops many years before symptom onset [3, 4].”
§ The use of neuroimaging techniques in the early and differential diagnosis of dementia > Introduction
What the sources say
- Partly supportedcites [3] Jansen WJ, Janssen O, Tijms BM, Vos SJB, Ossenkoppele R, Visser PJ, et al. Prevalence estimates of amyloid abnormality across the alzheimer disease clinical spectrum. JAMA Neurol. 2022;79:228–43. sourceExperimental — accuracy not yet measured
The Discussion says amyloid aggregation is an early marker that becomes abnormal years before dementia onset. That supports pre-onset pathology in Alzheimer disease, but the paper does not establish the claim for all degenerative dementias or show that pathology is established before the onset of any symptoms. (LLM, conf=0.88)
- Partly supportedcites [4] Sirkis DW, Bonham LW, Johnson TP, La Joie R, Yokoyama JS. Dissecting the clinical heterogeneity of early-onset Alzheimer’s disease. Mol Psychiatry. 2022;27:2674–88. sourceExperimental — accuracy not yet measured
The “Amyloid-positivity in asymptomatic individuals” section reports amyloid-PET signal emerging 15–25 years before expected symptom onset and describes a long preclinical phase in Alzheimer’s disease. The paper does not extend that finding to all degenerative dementias. Page numbers were not provided in our copy. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and can also help with the differential diagnosis of dementia based on characteristic patterns of atrophy, white matter changes and the presence or absence of cerebrovascular disease [10].”
§ The use of neuroimaging techniques in the early and differential diagnosis of dementia > Structural MRI
What the sources say
- Supportedcites [10] Harper L, Barkhof F, Scheltens P, Schott JM, Fox NC. An algorithmic approach to structural imaging in dementia. J Neurol Neurosurg Psychiatry. 2014;85:692–8. source
The Introduction says structural imaging features help narrow the differential diagnosis. The cerebral atrophy assessment section identifies diagnostically useful patterns of atrophy, while the assessment of signal change section describes white-matter changes and the presence or absence of cerebrovascular damage as relevant to distinguishing causes of cognitive impairment. Page numbers were not provided in our copy. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“vascular cognitive impairment and VaD are associated with cortical and subcortical vascular changes (latter including white matter hyperintensities (WMH), lacunes, enlarged perivascular spaces and microbleeds) [11, 12].”
§ The use of neuroimaging techniques in the early and differential diagnosis of dementia > Structural MRI
What the sources say
- Not checked — no full text of the sourcecites [11] Harper L, Barkhof F, Fox NC, Schott JM. Using visual rating to diagnose dementia: a critical evaluation of MRI atrophy scales. J Neurol Neurosurg Psychiatry. 2015;86:1225–33. source
- Supportedcites [12] Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12:822–38. source
The Introduction (page unavailable) identifies small vessel disease as a common vascular cause of dementia and lists white matter hyperintensities, lacunes, prominent perivascular spaces, and microbleeds as its imaging signs. The sections on lacunes and cerebral microbleeds (pages unavailable) describe subcortical lacunes and microbleeds at the cortico-subcortical junction, supporting the stated anatomical range. (LLM, conf=0.87)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
82 more claims · 50 with their cited sources checked
Create a free account to see all 150 claims and to verify the 42 references still open.
- It may state two separate claims as one. 60
- Probably not a substantial claim. 8
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“In a multicentre cross-sectional study that included 719 participants (150 controls, 126 MCI, 170 AD and 254 other neurodegenerative disorder), 18F-flortaucipir PET had 89.9% sensitivity and 90.6% specificity in discriminating AD from non-AD neurodegenerative disorders”
§ The use of neuroimaging techniques in the early and differential diagnosis of dementia > Tau PET imaging
Reported 719 · recomputed 700
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“…of dementia is important for a number of reasons, including optimising clinical management, offering opportunities for secondary prevention, increasing prognostic accuracy and the identi fi cation of the right people to bene fi t from disease modifying therapies, once these become available [5 – 7].”
Cited work 10.1016/s0140-6736(20)30367-6 · retracted 2023-05-01 · notice 10.1016/s2468-2667(23)00083-x · this paper published 2023-08-22
Citations
Cites
1 retracted
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430 · cited 1×
“…of dementia is important for a number of reasons, including optimising clinical management, offering opportunities for secondary prevention, increasing prognostic accuracy and the identi fi cation of the right people to bene fi t from disease modifying therapies, once these become available [5 – 7].”
BackgroundRetractedLecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678 · cited 1×
“…of dementia is important for a number of reasons, including optimising clinical management, offering opportunities for secondary prevention, increasing prognostic accuracy and the identi fi cation of the right people to bene fi t from disease modifying therapies, once these become available [5 – 7].”
BackgroundWardlaw, J. M., Smith, E. E., Biessels, G. J., Cordonnier, C., Fazekas, F., Frayne, R., Lindley, R. I., O'Brien, J. T., Barkhof, F., Benavente, O. R., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70124-8 · Cited by 5,544 · cited 1×
“…preservation of the hippocampus and occipital and subcortical atrophy while vascular cognitive impairment and VaD are associated with cortical and subcortical vascular changes (latter including white matter hyperintensities (WMH), lacunes, enlarged perivascular spaces and microbleeds) [11, 12].”
BackgroundSelf-citationDiagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
Self-citationClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 1×
“In dominantly inherited AD, hypometabolism on FDG-PET can be detected as early as 10 years before symptom onset [112].”
BackgroundNODDI: Practical in vivo neurite orientation dispersion and density imaging of the human brain
Zhang, H., Schneider, T., Wheeler-Kingshott, C. A., & Alexander, D. C. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.03.072 · Cited by 3,288 · cited 1×
“NODDI is a DTI technique that derives measures of orientation dispersion index and neurite density index and can detect distinct microstructural features [88].”
MethodNeuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“Anti-A β immunotherapies have shown reductions in amyloid PET and several amyloid reducing therapies for AD use amyloid PET (or CSF) as a key endpoint [172, 173].”
Background2019 Alzheimer’s disease facts and figures.
Alzheimer's Association (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.010 · Cited by 2,461 · cited 1×
“Dementia, the umbrella term for global cognitive decline causing functional impairment, affects ~55 million people worldwide [1].”
BackgroundBlood-brain barrier breakdown in the aging human hippocampus
Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.032 · Cited by 2,102 · cited 1×
“…dynamic contrast-enhanced MRI with temporal and spatial resolutions to measure BBB permeability have shown a breakdown of the BBB in the hippocampus of patients with early cognitive dysfunction, independent of their amyloid and tau biomarker status and this also occurs in normal aging [73, 74].”
Background
Cited by
Kale, M., Wankhede, N., Pawar, R., Ballal, S., Kumawat, R., Goswami, M., Khalid, M., Taksande, B., Upaganlawar, A., Umekar, M., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102497 · Cited by 183
Raza, M. L., Hassan, S. T., Jamil, S., Hyder, N., Batool, K., Walji, S., & Abbas, M. K. (2025) · Frontiers in Neuroinformatics · doi:10.3389/fninf.2025.1557177 · Cited by 74
Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer’s Disease
Pradeepkiran, J. A., Baig, J., Islam, M. A., Kshirsagar, S., & Reddy, P. H. (2024) · Aging and Disease · doi:10.14336/ad.2024.0286 · Cited by 101
Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit
Høilund‐Carlsen, P. F., Alavi, A. A., Barrio, J. R., Castellani, R. J., Costa, T., Herrup, K., Kepp, K. P., Neve, R. L., Perry, G. L., Revheim, M.-E. R., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102348 · Cited by 45
Gut microbial metabolites and the brain–gut axis in Alzheimer’s disease: A review
Ji, X., Wang, J., Lan, T., Zhao, D., & Xu, P. (2025) · Biomolecules and Biomedicine · doi:10.17305/bb.2025.12921 · Cited by 44
“Initially, atrophy is localized to the medial temporal lobe, particularly the hippocampus and parahippocampal gyrus, which are critically involved in memory consolidation [13, 14].”
Metadata
- Authors
- Chouliaras, L., & O’Brien, J. T.
- Affiliations
- University of Cambridge (GB)
- Venue
- Molecular Psychiatry
- Published
- 2023-08-22
- Volume
- 28
- Issue
- 10
- Pages
- 4084-4097
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC10827668
- OpenAlex
- W4386050192
- Cited by
- 221
- References
- 258
- Citations by year
- 2026: 81 · 2025: 105 · 2024: 33 · 2023: 2
- FWCI
- 8.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Molecular Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- National Institute for Health and Care Research ((NIHR203312, CL-2017-14-007)
- Department of Health and Social Care
- NIHR Cambridge Biomedical Research Centre (NIHR 203312)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- dementia, differential diagnosis, early diagnosis, Alzheimer's disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia, structural MRI, 18F-FDG PET, amyloid PET, tau PET, dopaminergic imaging, [11C]UCB-J, synaptic imaging, prodromal dementia, multimodal neuroimaging
- MeSH terms
- Alzheimer Disease, Diagnosis, Differential, Humans, Lewy Body Disease, Positron-Emission Tomography, Frontotemporal Dementia, Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The use of neuroimaging techniques in the early and differential diagnosis of dementia. https://app.cochat.ai/papers/10.1038/s41380-023-02215-8
- The paper
- Chouliaras, L., & O’Brien, J. T. (2023). The use of neuroimaging techniques in the early and differential diagnosis of dementia. Molecular Psychiatry. https://doi.org/10.1038/s41380-023-02215-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.